Coherus BioSciences Inc.
www.coherus.com
Latest From Coherus BioSciences Inc.
Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Stada Ranibizumab Deal Doesn’t Change Coherus’ Aspirations
With one foot already in oncology, biosimilars player Coherus is looking to make a splash in ophthalmology with ambitions to launch rivals to Lucentis and Eylea, as well as Avastin, in the US in the coming years. The US-based firm has acknowledged the competition it faces for biosimilars to Lucentis as Bausch Health picked up rights to Stada and Xbrane’s candidate earlier this month.
Coherus Eyes Further Biosimilar Candidates But Urges Caution
Coherus BioScienes has an extra $200m or so in the bank thanks to a financing round complete last month. The company has committed to building out its pipeline of biosimilar candidates, while eyeing the opportunity to increase its share in the biosimilar pegfilgrastim market.
Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
- Generic Drugs
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Dermatology
- Gastrointestinal
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Ophthalmic
- Alias(es)
- BioGenerics Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Coherus BioSciences Inc.
- Senior Management
-
Dennis Lanfear, Chmn., Pres. & CEO
Jean-Frederic Viret, PhD, CFO
Vladimir Vexler, PhD, CSO
Barbara K Finck, MD, Acting CMO
Vince Anicetti, COO
Erik Wiberg, EVP, Corp. Dev. - Contact Info
-
Coherus BioSciences Inc.
Phone: (800) 794-5434
333 Twin Dolphin Dr., Ste. 600
Redwood City, CA 94065
USA